Modified GTX as second-line therapy for advanced pancreatic adenocarcinoma

Hana Ajouz, Deborah Mukherji, Ali Haydar, Ahmad Sharif Yakan, Ahmad Saleh, Elias Elias, Sally Temraz, Walid Faraj, Mohammad Khalife, Ali Shamseddine

Research output: Contribution to journalArticlepeer-review


Background: Advanced pancreatic cancer remains a lethal disease with no standard treatment beyond first-line palliative chemotherapy. Gemcitabine, docetaxel, and capecitabine (GTX) is a regimen that has come into use for advanced pancreatic cancer despite a paucity of randomized data. Methods: We have used a modified schedule of this regimen in the second-line setting aimed at biomodulating the activity of capecitabine by both docetaxel and gemcitabine. This report describes our experience with the use of modified GTX in nine patients with advanced pancreatic cancer as second-line chemotherapy. Conclusion: In our series, the median overall survival was 8 months (range 5.2-10.8). Prospective studies of this regimen in the second-line setting are warranted.

Original languageEnglish (US)
Pages (from-to)109-112
Number of pages4
JournalJournal of Gastrointestinal Cancer
Issue number1
StatePublished - Mar 2014
Externally publishedYes


  • GTX
  • Pancreatic adenocarcinoma
  • Second-line chemotherapy

ASJC Scopus subject areas

  • Oncology
  • Gastroenterology


Dive into the research topics of 'Modified GTX as second-line therapy for advanced pancreatic adenocarcinoma'. Together they form a unique fingerprint.

Cite this